SynthesisThe Cochrane database of systematic reviews2009
Drugs for discoid lupus erythematosus.
Synthesis in The Cochrane database of systematic reviews, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Trends and collaborations in discoid lupus erythematosus research: a bibliometric analysis from 2010 to 2024.Frontiers in medicine · 2025Pooled it
- Interventions for cutaneous disease in systemic lupus erythematosus.The Cochrane database of systematic reviews · 2021Pooled it
- Drugs for discoid lupus erythematosus.The Cochrane database of systematic reviews · 2017Pooled it
- Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus.Arthritis research & therapy · 2012Trial
- The Use of Light-Based Therapies in the Treatment of Alopecia.Journal of cosmetic dermatology · 2025Review
- Advancements in the Treatment of Cutaneous Lupus Erythematosus and Dermatomyositis: A Review of the Literature.Clinical, cosmetic and investigational dermatology · 2022Review
- Oral and Maxillo-Facial Manifestations of Systemic Diseases: An Overview.Medicina (Kaunas, Lithuania) · 2021Review
- Article
- Current Insights Into The Management Of Discoid Lupus Erythematosus.Clinical, cosmetic and investigational dermatology · 2019Article
- Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review.Clinical drug investigation · 2018Review
- Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus.Current opinion in rheumatology · 2016Review
- Treatment of primary Sjögren syndrome.Nature reviews. Rheumatology · 2016Review
- Ruxolitinib Attenuates Cutaneous Lupus Development in a Mouse Lupus Model.The Journal of investigative dermatology · 2015Article
- From pathogenesis, epidemiology, and genetics to definitions, diagnosis, and treatments of cutaneous lupus erythematosus and dermatomyositis: a report from the 3rd International Conference on Cutaneous Lupus Erythematosus (ICCLE) 2013.The Journal of investigative dermatology · 2015Article
- Pragmatic approaches to therapy for systemic lupus erythematosus.Nature reviews. Rheumatology · 2014Review
- Cutaneous lupus erythematosus: An update.Indian dermatology online journal · 2014Review
- The Cochrane Skin Group: a vanguard for developing and promoting evidence-based dermatology.Journal of evidence-based medicine · 2013Article
- Review
- Cutaneous lupus erythematosus: diagnosis and treatment.Best practice & research. Clinical rheumatology · 2013Review
- Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria.The Journal of clinical and aesthetic dermatology · 2013Article
Corrections and comments
- Updated by
- Update of
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiscoid lupus erythematosus is a chronic form of cutaneous (skin) lupus which can cause permanent scarring if treatment is inadequate. Many drugs have been used to treat this disease and some of these are potentially very toxic.
objectivesTo assess the effects of drugs for discoid lupus erythematosus. SEARCH STRATEGY: In June 2009 we updated our searches of the Cochrane Skin Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (Issue 2, 2009), MEDLINE, EMBASE, LILACS, and online ongoing trials registers. The reference lists of relevant reviews were searched. Index Medicus (1956 to 1966) was handsearched and we approached authors for information about unpublished trials. SELECTION CRITERIA: We included all randomised trials of drugs to treat people with discoid lupus erythematosus. Drugs included in the search were azathioprine, chloroquine, clofazimine, corticosteroids, (oral and topical), dapsone, gold, interferon alpha-2a, methotrexate, phenytoin, retinoids, sulphasalazine, thalidomide, topical calcineurin blockers (pimecrolimus and tacrolimus), and biological agents (etanercept, efalizimab, infliximab, and rituximab). DATA COLLECTION AND ANALYSIS: Two reviewers independently examined each retrieved study for eligibility. MAIN
resultsTwo trials involving 136 participants were included. No new trials were included in this update.In a cross-over study of 12 weeks duration, fluocinonide 0.05% cream (a potent topical corticosteroid), appeared to be better than hydrocortisone 1% cream (a mild corticosteroid) when the first arm of the trial involving 78 participants was analysed at 6 weeks. Clearing or excellent improvement was seen in 27% of people using fluocinonide and in 10% of those using hydrocortisone, giving a 17% absolute benefit in favour of fluocinonide (95% CI 0.0 to 0.34, NNT (Number needed to treat) 6).In the second trial, acitretin (50mg/day) was compared with hydroxychloroquine (400mg/day) in 58 people in a parallel trial of 8 weeks duration. There was marked improvement or clearing in 46% of people using acitretin and in 50% of those on hydroxychloroquine but there was no significant difference between the 2 interventions. The adverse effects were more frequent and more severe in the acitretin group. In this trial clearing of erythema was measured and found to be better in the hydroxychloroquine group (RR 0.61, 95% CI 0.36 to 1.06). AUTHORS'
conclusionsFluocinonide cream may be more effective than hydrocortisone in treating people with discoid lupus erythematosus. Hydroxychloroquine and acitretin appear to be of equal efficacy, although adverse effects are more frequent and more severe with acitretin. There is not enough reliable evidence about other drugs used to treat discoid lupus erythematosus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.